Transcripta Bio raises $24 million in a Series A funding round led by Mayo Clinic and Omnimed to advance AI-powered drug discovery for neurological diseases.
Amount Raised
$24 Million
Round Type
Series A
Palo AltoBiotechnologyHealth CareArtificial IntelligenceTherapeuticsInvestors
Description
Transcripta Bio has announced it raised $24 million since its Series A. The funding will be used to advance IND-enabling studies and support clinical preparation for programs targeting Autism Spectrum Disorder and Facioscapulohumeral Muscular Dystrophy. The round included new participation from Mayo Clinic and Omnimed alongside existing investors. This capital aims to enhance their AI-powered drug discovery platform.
Quick answer
Transcripta Bio raised $24 Million in a Series A round, dated July 22, 2026. Investors: BlueYard Capital, JAZZ Venture Partners, Mayo Clinic and Omnimed. Transcripta Bio is based in Palo Alto, California, United States.
- How much did Transcripta Bio raise?
- Transcripta Bio raised $24 Million in a Series A round on July 22, 2026.
- Who invested in Transcripta Bio?
- BlueYard Capital, JAZZ Venture Partners, Mayo Clinic and Omnimed are named as investors in this round.
- What does Transcripta Bio do?
- Transcripta Bio is an AI-powered drug discovery company that focuses on developing treatments for neurological and neuromuscular diseases.
- Where is Transcripta Bio based and how big is it?
- Transcripta Bio is based in Palo Alto, California, United States. Fundz records about 19 employees.
- Who are the decision-makers at Transcripta Bio?
- Fundz holds 1 contact at Transcripta Bio, including the CEO. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Transcripta Bio that raised within 45 days of this round, from Fundz verified event records.
- Sightera Biosciences raised $3.4M (Pre-Seed) on July 17, 2026.
- AbSci Corp raised $40M (Funding Round) on July 1, 2026.
- Graph Therapeutics raised $5M (Funding Round) on June 22, 2026.
- Dimerix Limited raised $25M (Debt Financing) on September 4, 2026.
- ZoeNCure Therapeutics Pvt. Ltd raised $2.4M (Seed) on September 3, 2026.
- NovaGo Therapeutics raised $30M (Series B) on September 2, 2026.
Who to call at Transcripta Bio, and when
A new round usually means Transcripta Bio is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Transcripta Bio raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Transcripta Bio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Transcripta Bio. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Transcripta Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansTranscripta Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.